Literature DB >> 8840278

Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059.

C Serradeil-Le Gal1, D Raufaste, E Marty, C Garcia, J P Maffrand, G Le Fur.   

Abstract

Localization and characterization of binding sites of the selective non-peptide vasopressin receptor V1a ligand, [3H]-SR 49059, were investigated in the adult rat kidney by quantitative autoradiography using a fast-detecting radioluminographic phosphor-imaging plate system. [3H]-SR 49059, like the other V1a ligands used, showed a total absence of binding in the papilla, discrete and sparse labeling in the cortex and maximal binding in the outer part of the inner medulla. This labeling seemed to be mainly associated with medullary interstitial cells and vascular elements of the vasa recta. Conversely, [3H]-AVP intensely labeled the V2-enriched medulla-papillary portion of the kidney and, to a lesser extent, the cortical structures. [3H]-SR 49059 binding, quantified in the outer part of the inner medulla in rat kidney sections, was time-dependent, reversible, saturable and a single class of high affinity binding sites (Kd = 1.48 +/- 0.16 nM) was identified. The relative potencies of the reference peptide and non-peptide compounds to inhibit [3H]-SR 49059 binding confirm the V1a nature of the site and the stereospecificity of this binding. Thus, [3H]-SR 49059 allows the mapping and characterization of the V1a receptor population present in the rat kidney. The stability and the highly selective affinity of this non-peptide ligand for rat and human V1a receptors make it a suitable probe for the localization of V1a receptors in organs expressing heterogeneous populations of receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840278     DOI: 10.1038/ki.1996.341

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

3.  Vasopressin Increases Urinary Acidification via V1a Receptors in Collecting Duct Intercalated Cells.

Authors:  Torsten Giesecke; Nina Himmerkus; Jens Leipziger; Markus Bleich; Taka-Aki Koshimizu; Michael Fähling; Alina Smorodchenko; Julia Shpak; Carolin Knappe; Julian Isermann; Niklas Ayasse; Katsumasa Kawahara; Jan Schmoranzer; Niclas Gimber; Alexander Paliege; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2019-05-16       Impact factor: 10.121

4.  Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling.

Authors:  Elena A Zalyapin; Richard Bouley; Udo Hasler; Jean-Pierre Vilardaga; Herbert Y Lin; Dennis Brown; Dennis A Ausiello
Journal:  Kidney Int       Date:  2008-08-27       Impact factor: 10.612

5.  Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.

Authors:  Julie Perucca; Daniel G Bichet; Pascale Bardoux; Nadine Bouby; Lise Bankir
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.